| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0208d5130c7e8ef59f2040412bb6c9a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9311576b12a576f31f65745e20634b6c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0697
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2529-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-32 |
| filingDate |
2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7885e0c8883868ab19e2e773900cd7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1ff7f6a999627d5a547462fd534ddf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e2b9b022b7d7fe6cd2013c3d262e176
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86fec59221798ce81b4c9ce0cfde69e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9f1abea766f6e81d5ee362d154c2c96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e0c3e92cb77c2cf0fd3b95bcf9b1104 |
| publicationDate |
2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018290628-B2 |
| titleOfInvention |
Pharmaceutical composition for preventing or treating osteoarthritis |
| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating osteoarthritis comprising a cell or a cell group having a specific size or less, a kit for preparing a cellular therapeutic agent, and a method for preparing a therapeutic agent for osteoarthritis. Mixed cells, which are selected to be equal to or less than a specific size as an effective ingredient of the present invention, of mammalian cells transformed with TGF-β and untransformed mammalian cells minimize aggregation between chondrocytes and have a beneficial therapeutic effect. In addition, when the mixed cells of the selected specific size or less are administered to a patient, patient compliance may be improved, and it is easy to manage quality in a therapeutic agent production facility or a hospital. |
| priorityDate |
2017-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |